× Industry Reports Services Press Release Contact us About us

Europe Cell Line Development Market Forecast 2027 By Cell Line (Recombinant, Hybridomas, Continuous Cell Line, Primary Cell Line), By Product (Reagents & Media, Equipment {Incubator, Centrifuge, Bioreactor, Storage Equipment, Microscope}, Accessories & Consumables), By Source (Mammalian, Non-mammalian {Insects, Amphibians}), By Application (Bioproduction, Drug Discovery, Toxicity Testing, Tissue Engineering, Research), Research Report, Country Outlook (Germany, UK, France, Spain, Italy, Russia, Ukraine, Poland, Switzerland, Belgium, Greece, Czech Republic, Netherlands, Sweden), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share
Published Date: September 2021 | Publisher: Graphical Research Report ID: GR1066 | Delivery : PDF  Request Free Sample

Europe Cell Line Development Market size crossed USD 1.1 billion in 2020 and is predicted to register a growth of 11% from 2021 to 2027.

Increasing demand of monoclonal antibodies is a key factor driving the market revenue. Monoclonal antibodies work as immunotherapy that supports immune system to respond better and effectively. Monoclonal antibodies play important role in cancer diagnosis and other immune diseases. Rapidly increasing regulatory approval for monoclonal antibody use for various diseases will create new opportunities for market players to expand their product portfolio of cell line development.

Europe Cell Line Development Market

Get more details on this report - Request Free Sample PDF

Europe Market, By Product

Reagents & media product segment in the Europe cell line development market is anticipated to expand at nearly 11% CAGR through 2027. Recurring demand for reagents and media during the cell line development process and increasing R&D activities for drug discovery and development are some of the major factors pushing the segment growth.

Europe Market, By Source

Mammalian segment accounted for 72% market share in 2020. Mammalian cells can be made to produce vaccines through viral infection using genetic engineering. Mammalian cell lines are commonly used during the drug development processes. These drugs are use in the treatment of genetic diseases, cancer and more. Advancement in technology will improve the efficiency of highly productive cell lines for large scale production of therapeutic proteins.

Europe Market, By Cell Line Type

Europe Cell Line Development Market, By Cell Line Type

Get more details on this report - Request Free Sample PDF

Primary cell line segment held more than 19% market share in 2020. Primary cell line is derived from specific organ of a species, and it isolated directly by using mechanical or enzymatic methods. These cells are further used in research, drug screening and development, manufacturing of biological compounds such as vaccines, therapeutic proteins.

Europe Market, By Country

Germany cell line development market size was over USD 211 million in 2020 and will exhibit more than 10% CAGR during the forecast period. Rising R&D activities for chronic disease and increasing demand of vaccines and therapeutic proteins will spur the industry growth.

Competitive Industry Landscape

Key companies operating in the Europe cell line development market are GVK BIO, Sartorius, WuXi AppTec, Thermo Fisher Scientific, Samsung Biologics, The European Collection of Cell Cultures, Lonza Group, Sigma-Aldrich (Merck), GE Healthcare, and Selexis SA.

Market players are focusing on new product launch, collaborations, mergers and acquisitions to strengthen company position in the industry. For instance, in May 2019, Sartorius Stedim Biotech launched an Ambr 15 cell culture automated microbioreactor system. The system increases lab productivity during cell line development.
 

Frequently Asked Question(FAQ) :

The market share for cell line development in Europe was surpassed USD 1.1 billion in 2020 and will grow at over 11% CAGR through 2027 led by the growing demand for monoclonal antibodies.
Reagents & media segment will expand at an 11% CAGR in Europe market due to increasing R&D activities for drug discovery and development.
Mammalian segment captured more than 72% of Europe industry share in 2020 owing to wide use in genetic engineering for vaccine production.
The market for primary cell line development in Europe accounted for over 19% revenue share in 2020 owing to growing use in research, drug screening, and development.
The market size for cell line development in Germany was recorded at USD 211 million in 2020 and should witness a 10% CAGR up to 2027 led by the growing demand for vaccines and therapeutic proteins.

Premium Report

Have questions?
  • Inquire Before Buying
  • Why Choose us?

    • on-time delivery On-Time Delivery

      We commit to on-time delivery of reports to keep you ahead.

    • assured quality Assured Quility

      With a wide network of industry experts and trained in-house analysts, we assure best service quality.

    • Custom Research Service

      We offer research services to meet specific client requirements and provide them with actionable insights on target markets.

    • payment security Payment Security

      Our safe payment gateway gives you full control of your personal data, at all times.

    Connect with our sales team

     1-800-986-6917

     [email protected]